Finance

Beta
Lists
PSTV:NASDAQ
Plus Therapeutics Inc
$5.41
-5.83%
(-0.34) 1D
$5.23
-3.33% (-0.18)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PSTV...
Open
$5.60
High
$5.62
Low
$5.17
Mkt. cap
37.21M
Avg. vol.
149.31K
Volume
120.36K
52-wk high
$23.42
52-wk low
$2.90
EPS
-$2.50
Beta
1.38
Shares outstanding
6.88M
No. of employees
28
Open
$5.60
High
$5.62
Low
$5.17
Mkt. cap
37.21M
Avg. vol.
149.31K
Volume
120.36K
52-wk high
$23.42
52-wk low
$2.90
EPS
-$2.50
Beta
1.38
Shares outstanding
6.88M
No. of employees
28
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to PSTV in the past 3 months
Strong Buy
Buy
4
Hold
1
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PSTV in the last 3 months.
Highest
Current $5.41
$65.00 (+1,101.48%)
Average
$38.00 (+602.40%)
Lowest
$12.00 (+121.81%)
News stories
From sources across the web
Profile
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Plus Therapeutics Inc
CEO-
Employees28
Founded1996
Headquarters-
SectorBiotechnology
Websiteplustherapeutics.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.06M
1.39M
1.40M
1.37M
Cost of goods sold
1.76M
1.25M
2.44M
2.94M
Cost of revenue
1.76M
1.25M
2.44M
2.94M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.84M
1.68M
3.44M
4.17M
Operating expense
2.84M
1.68M
3.44M
4.17M
Total operating expenses
4.60M
2.93M
5.88M
7.11M
Operating income
-3.54M
-1.54M
-4.48M
-5.74M
Other non operating income
-13.32M
6.66M
-
-
EBT including unusual items
-17.40M
5.15M
-4.42M
-5.71M
EBT excluding unusual items
-17.40M
5.15M
-4.42M
-5.71M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.40M
5.15M
-4.42M
-5.71M
Net profit margin
-1,643.15%
370.58%
-316.61%
-417.92%
Earnings per share
-14.17
-0.16
-1.00
-
Interest and investment income
1.00K
27.00K
59.00K
29.00K
Interest expense
-548.00K
-
-
-
Net interest expenses
-547.00K
27.00K
59.00K
29.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.39M
-1.46M
-4.40M
-5.60M
Gain or loss from assets sale
-16.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer